Abstracts tagged "rheumatoid arthritis"

Abstract Number: 981 • 2019 ACR/ARP Annual Meeting
Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models
Hani Manfred Sauermilch¹, Marie-Lisa Hülser ¹, Carina Schreiyäck ¹, Yubin Luo ², Aline Bozec ², Georg Schett ³, Ulf Müller-Ladner ⁴ and Elena Neumann ⁵, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Giessen, Germany, ²Department Clinic of Medicine 3 - Immunology and Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁴Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁵Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Giessen, Hessen, Germany
Background/Purpose: Adipocytokines are bioactive factors mainly produced by adipose tissue and exert many important effects on energy homeostasis as well as immune responses. Osteoarthritis (OA)…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1966 • 2019 ACR/ARP Annual Meeting
A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis
Ki-Nam Gu ¹, So-Young Bang², Hye-Soon Lee ³, Youngho Park ², Juyeon Kang ², Ji-Soong Kim ², Bora Nam ², Hyun-Seung Yoo ⁴, Jung-Min Shin ², Yeon-Kyung Lee ², Tae-Han Lee ², Sehwan Chun ¹, Soo-Kyung Cho ², Chan-Bum Choi ², Yoon-Kyoung Sung ⁵, Tae-Hwan Kim ², Jae-Bum Jun ², DaeHyun Yoo ², Kwangwoo Kim ¹ and Sang-Cheol Bae ², ¹Kyung Hee University, Seoul, Republic of Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Department of Internal Medicine, Hanyang University Guri Hospital,Hanyang University School of Medicine, Guri, Korea, Guri, Republic of Korea, ⁴Hanyang University Hospital, Guri, Republic of Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Copy number variation (CNV) is the most common structural variation defined as large ( >1 kb) genomic deletions and duplications and could yield a…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 101 • 2019 ACR/ARP Annual Meeting
CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases
Ye Chen¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State University, Columbus, OH, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Regulatory T (Treg) cells play an important role in maintaining immunologic homeostasis. Abnormal Treg cells were found in some autoimmune diseases. Transferred natural Treg…
Abstract Number: 527 • 2019 ACR/ARP Annual Meeting
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Roy Fleischmann¹, Jose Jeffrey Enejosa ², In-Ho Song ³, Eduardo Mysler ⁴, Louis Bessette ⁵, Charles Peterfy ⁶, Patrick Durez ⁷, Andrew Östör ⁸, Yijie Zhou ⁹ and Mark Genovese ¹⁰, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Laval University, Quebec City, QC, Canada, ⁶Spire Sciences Inc, Boca Raton, ⁷Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁸Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁹AbbVie Inc., North Chicago, ¹⁰Stanford University, Stanford, CA
Background/Purpose: In the SELECT-COMPARE study in rheumatoid arthritis (RA) patients (pts) with inadequate response to methotrexate (MTX), upadacitinib (UPA), a JAK1- selective inhibitor, was superior…
Abstract Number: 982 • 2019 ACR/ARP Annual Meeting
A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice
Ruth Napier¹, Emily Vance ¹, James O'Dell ², Jill Poole ³, Bryant England ⁴, Michael Duryee ³, Ted Mikuls ², Holly Rosenzweig ⁵ and Geoffrey Thiele ², ¹Oregon Health & Science University and Portland VA Hospital, Portland, OR, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ⁵Oregon Health & Science University and Portland VA Hospital, Oregon
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests in a chronic and debilitating polyarthritis. Although the etiology of RA is unknown pathogenic…
Abstract Number: 1382 • 2019 ACR/ARP Annual Meeting
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Jacob Greenmyer ¹, John Stacy ¹, James Beal ², Abe Sahmoun ² and Erdal Diri¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Glucocorticoids (GCs) are commonly used in RA patients as remission induction monotherapy or as bridging therapy when starting DMARD/biologic therapy. Despite the ubiquity of…
Abstract Number: 1996 • 2019 ACR/ARP Annual Meeting
Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Ra Ham Kim¹, Hyun Jung Yoo ², Shin Eui Kang ³, Ji soo Park ⁴, Seon Uk Kim ⁵, Eun Young Lee ⁶, Jin Kyun Park ⁶ and Yeong-Wook Song ⁷, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Repulbic of Korea, Seoul, Republic of Korea, ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁷Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder, characterized by joint inflammation and bone destruction. The fibroblast-like synoviocyte(FLS) contributes to the pathogenesis of RA…
Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 296 • 2019 ACR/ARP Annual Meeting
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Diana Vossen ¹, Valentin Schaefer², Florian Recker ³, Isabelle Geffken ⁴, Eva Matuschek ⁵ and Wolfgang Hartung ⁶, ¹Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ²Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn, Bonn, Germany, ³1. Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn and 2. Department for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ⁴Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St.Elisabeth Hospital, Düsseldorf, Germany, ⁵Department for Internal Medicine, Dreifaltigkeits-Krankenhaus Wesseling, bonn, Germany, ⁶Rheumatology und clinical Immunology, Asklepios Klinik, 93077 Bad Abbach, Bad Abbach, Germany
Background/Purpose: Musculoskeletal ultrasound is an important imaging method in the diagnosis of arthritis, especially rheumatoid arthritis (RA). The prevalence of elbow joint arthritis in RA…
Abstract Number: 529 • 2019 ACR/ARP Annual Meeting
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
Stephen Hall¹, Tsutomu Takeuchi ², Glen Thomson ³, Paul Emery ⁴, Bernard Combe ⁵, Andrea Everding ⁶, Karel Pavelka ⁷, Yanna Song ⁸, Tim Shaw ⁹, Alan Friedman ⁹, In-Ho Song ¹⁰ and Eduardo Mysler ¹¹, ¹Monash University and Emeritus Research, Melbourne, Australia, ²Keio University School of Medicine, Tokyo, Japan, ³CIADS Research, Winnipeg, Canada, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵CHU Montpellier, Montpellier University, Montpellier, France, ⁶HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁹AbbVie Inc., North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO)…
Abstract Number: 983 • 2019 ACR/ARP Annual Meeting
Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection
Teresina Laragione¹, Carolyn Harris ¹ and Percio Gulko ¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Magnesium (Mg) plays a key role in the immune response. We have previously demonstrated that alterations in the Mg balance by increasing or decreasing…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Ha-Reum Lee¹, Su-Jin Yoo ², Chan-Geol Park ², Jinhyun Kim ², In Seol Yoo ² and Seong Wook Kang ², ¹Chungnam National University Hospital,, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].